AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers

Ahmed Katsha, Janet Arras, Mohammed Soutto, Abbes Belkhiri, Wael El-Rifai

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aurora kinase A is a frequently amplified and overexpressed gene in upper gastrointestinal adenocarcinomas (UGCs). Using invitro cell models of UGCs, we investigated whether AURKA can regulate Signal Transducer and Activator of Transcription 3 (STAT3). Our data indicate that overexpression of AURKA in FLO-1 and AGS cells increase STAT3 phosphorylation at the Tyr705 site, whereas AURKA genetic depletion by siRNA results in decreased phosphorylation levels of STAT3 in FLO-1 and MKN45 cells. Immunofluorescence analysis showed that AURKA overexpression enhanced STAT3 nuclear translocation while AURKA genetic knockdown reduced the nuclear translocation of STAT3 in AGS and FLO-1 cells, respectively. Using a luciferase reporter assay, we demonstrated that AURKA expression induces transcriptional activity of STAT3. Pharmacological inhibition of AURKA by MLN8237 reduced STAT3 phosphorylation along with down-regulation of STAT3 pro-survival targets, BCL2 and MCL1. Moreover, by using clonogenic cells survival assay, we showed that MLN8237 single dose treatment reduced the ability of FLO-1 and AGS cells to form colonies. Additional experiments utilizing cell models of overexpression and knockdown of AURKA indicated that STAT3 upstream non-receptor tyrosine kinase Janus kinase 2 (JAK2) is mediating the effect of AURKA on STAT3. The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation. These results confirm that the AURKA-JAK2 axis is the main mechanism by which AURKA regulates STAT3 activity. In conclusion, we report, for the first time, that AURKA promotes STAT3 activity through regulating the expression and phosphorylation levels of JAK2. This highlights the importance of targeting AURKA as a therapeutic approach to treat gastric and esophageal cancers.

Original languageEnglish (US)
Pages (from-to)1419-1428
Number of pages10
JournalMolecular Oncology
Volume8
Issue number8
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Aurora Kinase A
Janus Kinase 2
STAT3 Transcription Factor
Esophageal Neoplasms
Human Activities
Stomach Neoplasms
Phosphorylation
Small Interfering RNA
Adenocarcinoma
Colony-Forming Units Assay

Keywords

  • Adenocarcinoma
  • Alisertib
  • AZD1480
  • Barrett's
  • BCL2
  • Esophageal
  • Gene regulation
  • MCL1
  • MLN8237
  • Stomach

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Cite this

AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. / Katsha, Ahmed; Arras, Janet; Soutto, Mohammed; Belkhiri, Abbes; El-Rifai, Wael.

In: Molecular Oncology, Vol. 8, No. 8, 01.12.2014, p. 1419-1428.

Research output: Contribution to journalArticle

Katsha, Ahmed ; Arras, Janet ; Soutto, Mohammed ; Belkhiri, Abbes ; El-Rifai, Wael. / AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. In: Molecular Oncology. 2014 ; Vol. 8, No. 8. pp. 1419-1428.
@article{ea7daac568f7413fbd8e323099fa536a,
title = "AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers",
abstract = "Aurora kinase A is a frequently amplified and overexpressed gene in upper gastrointestinal adenocarcinomas (UGCs). Using invitro cell models of UGCs, we investigated whether AURKA can regulate Signal Transducer and Activator of Transcription 3 (STAT3). Our data indicate that overexpression of AURKA in FLO-1 and AGS cells increase STAT3 phosphorylation at the Tyr705 site, whereas AURKA genetic depletion by siRNA results in decreased phosphorylation levels of STAT3 in FLO-1 and MKN45 cells. Immunofluorescence analysis showed that AURKA overexpression enhanced STAT3 nuclear translocation while AURKA genetic knockdown reduced the nuclear translocation of STAT3 in AGS and FLO-1 cells, respectively. Using a luciferase reporter assay, we demonstrated that AURKA expression induces transcriptional activity of STAT3. Pharmacological inhibition of AURKA by MLN8237 reduced STAT3 phosphorylation along with down-regulation of STAT3 pro-survival targets, BCL2 and MCL1. Moreover, by using clonogenic cells survival assay, we showed that MLN8237 single dose treatment reduced the ability of FLO-1 and AGS cells to form colonies. Additional experiments utilizing cell models of overexpression and knockdown of AURKA indicated that STAT3 upstream non-receptor tyrosine kinase Janus kinase 2 (JAK2) is mediating the effect of AURKA on STAT3. The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation. These results confirm that the AURKA-JAK2 axis is the main mechanism by which AURKA regulates STAT3 activity. In conclusion, we report, for the first time, that AURKA promotes STAT3 activity through regulating the expression and phosphorylation levels of JAK2. This highlights the importance of targeting AURKA as a therapeutic approach to treat gastric and esophageal cancers.",
keywords = "Adenocarcinoma, Alisertib, AZD1480, Barrett's, BCL2, Esophageal, Gene regulation, MCL1, MLN8237, Stomach",
author = "Ahmed Katsha and Janet Arras and Mohammed Soutto and Abbes Belkhiri and Wael El-Rifai",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.molonc.2014.05.012",
language = "English (US)",
volume = "8",
pages = "1419--1428",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers

AU - Katsha, Ahmed

AU - Arras, Janet

AU - Soutto, Mohammed

AU - Belkhiri, Abbes

AU - El-Rifai, Wael

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aurora kinase A is a frequently amplified and overexpressed gene in upper gastrointestinal adenocarcinomas (UGCs). Using invitro cell models of UGCs, we investigated whether AURKA can regulate Signal Transducer and Activator of Transcription 3 (STAT3). Our data indicate that overexpression of AURKA in FLO-1 and AGS cells increase STAT3 phosphorylation at the Tyr705 site, whereas AURKA genetic depletion by siRNA results in decreased phosphorylation levels of STAT3 in FLO-1 and MKN45 cells. Immunofluorescence analysis showed that AURKA overexpression enhanced STAT3 nuclear translocation while AURKA genetic knockdown reduced the nuclear translocation of STAT3 in AGS and FLO-1 cells, respectively. Using a luciferase reporter assay, we demonstrated that AURKA expression induces transcriptional activity of STAT3. Pharmacological inhibition of AURKA by MLN8237 reduced STAT3 phosphorylation along with down-regulation of STAT3 pro-survival targets, BCL2 and MCL1. Moreover, by using clonogenic cells survival assay, we showed that MLN8237 single dose treatment reduced the ability of FLO-1 and AGS cells to form colonies. Additional experiments utilizing cell models of overexpression and knockdown of AURKA indicated that STAT3 upstream non-receptor tyrosine kinase Janus kinase 2 (JAK2) is mediating the effect of AURKA on STAT3. The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation. These results confirm that the AURKA-JAK2 axis is the main mechanism by which AURKA regulates STAT3 activity. In conclusion, we report, for the first time, that AURKA promotes STAT3 activity through regulating the expression and phosphorylation levels of JAK2. This highlights the importance of targeting AURKA as a therapeutic approach to treat gastric and esophageal cancers.

AB - Aurora kinase A is a frequently amplified and overexpressed gene in upper gastrointestinal adenocarcinomas (UGCs). Using invitro cell models of UGCs, we investigated whether AURKA can regulate Signal Transducer and Activator of Transcription 3 (STAT3). Our data indicate that overexpression of AURKA in FLO-1 and AGS cells increase STAT3 phosphorylation at the Tyr705 site, whereas AURKA genetic depletion by siRNA results in decreased phosphorylation levels of STAT3 in FLO-1 and MKN45 cells. Immunofluorescence analysis showed that AURKA overexpression enhanced STAT3 nuclear translocation while AURKA genetic knockdown reduced the nuclear translocation of STAT3 in AGS and FLO-1 cells, respectively. Using a luciferase reporter assay, we demonstrated that AURKA expression induces transcriptional activity of STAT3. Pharmacological inhibition of AURKA by MLN8237 reduced STAT3 phosphorylation along with down-regulation of STAT3 pro-survival targets, BCL2 and MCL1. Moreover, by using clonogenic cells survival assay, we showed that MLN8237 single dose treatment reduced the ability of FLO-1 and AGS cells to form colonies. Additional experiments utilizing cell models of overexpression and knockdown of AURKA indicated that STAT3 upstream non-receptor tyrosine kinase Janus kinase 2 (JAK2) is mediating the effect of AURKA on STAT3. The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation. These results confirm that the AURKA-JAK2 axis is the main mechanism by which AURKA regulates STAT3 activity. In conclusion, we report, for the first time, that AURKA promotes STAT3 activity through regulating the expression and phosphorylation levels of JAK2. This highlights the importance of targeting AURKA as a therapeutic approach to treat gastric and esophageal cancers.

KW - Adenocarcinoma

KW - Alisertib

KW - AZD1480

KW - Barrett's

KW - BCL2

KW - Esophageal

KW - Gene regulation

KW - MCL1

KW - MLN8237

KW - Stomach

UR - http://www.scopus.com/inward/record.url?scp=84911978753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911978753&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.05.012

DO - 10.1016/j.molonc.2014.05.012

M3 - Article

C2 - 24953013

AN - SCOPUS:84911978753

VL - 8

SP - 1419

EP - 1428

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 8

ER -